BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
288 hedge funds and large institutions have $9.81B invested in bluebird bio in 2019 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 106 increasing their positions, 79 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
288
Holders Change
+37
Holders Change %
+14.74%
% of All Funds
6.24%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
65
Increased
106
Reduced
79
Closed
28
Calls
$141M
Puts
$87.5M
Net Calls
+$53.9M
Net Calls Change
-$26.9M
Top Buyers
| 1 |
MWNA
Marshall Wace North America
New York
|
+$74.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$58.4M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$49.1M |
| 4 |
HM
HealthCor Management
New York
|
+$47.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.5M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$38.4M |
| 2 |
Two Sigma Investments
New York
|
-$25.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.6M |
| 5 |
AG
Artal Group
Luxembourg
|
-$11.8M |
